chartexchange

Hemab Therapeutics Holdings Inc (COAG) (Q3 2026) Earnings Call Highlights: Pivotal SOLARA Trial ...

GuruFocus | Nov 11, 2026 6:03 PM EST

Hemab Therapeutics Holdings Inc (COAG) advances its subcutaneous bleeding disorder pipeline with a Phase III Glanzmann thrombasthenia study, promising HMB002 data, and funding through 2029. Related Stocks: COAG ,

Read original article